Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 3/20 | 0.71 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933577 | 0.85 | MAOB (0.76) | MAOBMAOAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1092229 | 0.85 | MAOB (1.00) | MAOBMAOAPARP10ALDH1A1HTT | |
| SCHEMBL6412631 | 0.85 | NR4A2 (1.00) | MAOBNR4A2PARP10SMN1; SMN2 | |
| SCHEMBL13171383 | 0.84 | MAOB (0.71) | MAOBNR4A2MAOAPARP10ALDH1A1 | |
| SCHEMBL18477946 | 0.84 | MAOB (0.73) | MAOBNR4A2MAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL25081212 | 0.84 | MAOB (0.72) | MAOBNR4A2MAOAPARP10ALDH1A1 | |
| SCHEMBL6418760 | 0.84 | MAOB (0.72) | MAOBNR4A2PARP10ALDH1A1HTT | |
| SCHEMBL10263162 | 0.83 | MAOB (0.71) | MAOBNR4A2MAOAPARP10ALDH1A1 | |
| SCHEMBL9778577 | 0.83 | MAOB (1.00) | MAOBNR4A2MAOAALDH1A1HTT | |
| SCHEMBL16395775 | 0.83 | MAOB (1.00) | MAOBMAOAALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2025-05-08 | — | — | US | disclosed |
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3704105-B1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2024-10-16 | — | — | EP | disclosed |
| CN-111566099-B | Antibacterial compounds | 迪斯库瓦有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | ASAH2, ASAH1, ACER2 | MAOB 936/4885NR4A2 4304/4885MAOA 677/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | MAOB 245/4885NR4A2 2569/4885MAOA 422/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NRDC, PGLS | MAOB 1843/4885NR4A2 3452/4885MAOA 2399/4885 |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, MRPL21, NQO1 | MAOB 245/4885NR4A2 2569/4885MAOA 422/4885 |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885NR4A2 2849/4885MAOA 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.